HF
STLN

HRT Financial’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

HRT Financial’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,658
Closed -$18K – 3521
2025
Q1 		$18K Buy
+16,658
New +$12.9K ﹤0.01% 2313

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

HRT Financial's STLN Position: Q2 2025 in Review

HRT Financial sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2025, closing a stake of 16,658 shares — an estimated $18K sold.

HRT Financial first reported a position in STLN in Q1 2025 and held it in 1 quarter. The position peaked at $18K in Q1 2025. 79 funds tracked by Wall St. Rank hold STLN as of Q2 2025.

  • HRT Financial reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 16,658 Starling Oncology Institute, Inc. Common Stock shares in Q2 2025, an estimated $18K.
  • HRT Financial first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2025 and held it in 1 quarter.
  • HRT Financial's Starling Oncology Institute, Inc. Common Stock position peaked at $18K in Q1 2025.
  • 79 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.